Among 17,604 non-diabetic patients with established atherosclerotic cardiovascular disease and overweight or obesity in the SELECT trial, semaglutide reduced high-sensitivity CRP by 37.8% at 104 weeks. Critically, this anti-inflammatory effect appeared within 4–8 weeks — before meaningful weight loss occurred — and persisted even among participants who lost no weight at all. Baseline hsCRP proved prognostic across three risk tiers (<2, 2–<10, ≥10 mg/L), with MACE risk escalating significantly across strata. hsCRP reductions were independent of LDL-cholesterol, statin use, and trial entry criteria, and modeling identified inflammation reduction as a partial independent contributor to semaglutide's cardiovascular benefit.
This finding meaningfully reframes semaglutide's cardiovascular mechanism. The prevailing assumption has been that GLP-1 receptor agonists reduce cardiac events primarily through weight loss and metabolic improvement. The speed and weight-independence of the hsCRP signal instead implicate direct vascular or immune-modulatory effects — possibly via GLP-1 receptors on macrophages or endothelial cells, a mechanism increasingly supported in preclinical literature. This echoes the CANTOS trial's logic that targeting inflammation per se reduces MACE, but here the effect arrives as a secondary benefit of an already-approved drug rather than a dedicated anti-inflammatory agent. Limitations include the observational nature of this biomarker substudy within an RCT — causality between hsCRP reduction and MACE reduction is modeled, not proven. Still, for clinicians managing high-hsCRP cardiovascular patients who cannot achieve weight loss, this is a paradigm-shifting signal warranting prospective validation.
